[ad_1]
Analysts Expect Icon Plc (ICLR) Will Announce Sales Quarterly of $ 633.83 Million Business Share Facebook Twitter LinkedIn Pinterest [ad_1] Source link Share Facebook Twitter LinkedIn Pinterest Tags analysts announce expect ICLR Icon million PLC Quarterly sales Related Articles Entekra opens a new European headquarters in Monaghan Stochastic RSI under discussion for Sohu.com Inc (SOHU) BREAK: "significant disturbance" train services after an incident on the line Tullow Oil cash forecast ups chances of dividend Lannett (LCI) Reports Financial Results Oakbrook Investments LLC Has $ 824,000 Position in Signature Bank (NASDAQ: SBNY)
![Icon logo "title =" Icon logo "clbad =" companylogo "/> Wall Street Analysts Expect Icon Plc (NASDAQ: ICLR) to announce $ 633.83 million in sales, Zacks reports. Icon sales, with $ 636.06 million and the lowest estimate coming in at $ 632.48 million. Icon posted sales of $ 431.02 million last year, which suggests a positive year-over-year growth rate of 47.1% Posted on Thursday, July 26th </p>
<p> On average, badysts expect that $ 2.57 billion for the current fiscal year, with charges ranging from $ 2.55 billion to $ 2.58 billion.For the next financial year, badysts anticipate that the business will report sales of $ 2.76 trillion per share, with estimates ranging from $ 2.71 trillion to $ 2.84 trillion. </p>
<p> Icon (NASDAQ: ICLR) last released its earnings on Thursday, May 3rd. The medical research company reported $ 1.42 per share for the quarter, topping the consensus estimate of $ 1.41 per $ 0.01. The company had revenue of $ 620.13 million for the quarter, compared to $ 562.61 million. Had a return on equity of 26.56% and a net margin of 14.80%. Icon's quarterly revenue was up 43.6% on a year-over-year basis. During the same period in the prior year, the firm posted $ 1.29 EPS. </p>
<p> Several badysts recently weighed in on ICLR shares. BidaskClub Raised Icon from a "hold" rating to a "buy" rating in a research note on Wednesday, March 28th. Zacks Investment Research Raised from a "hold" rating to a "buy" rating and a $ 134.00 price objective on the stock in a research note on Wednesday, April 18th. Jefferies Financial Group has raised its price to $ 150.00 and has given the company a "buy" rating in a research note on Friday, June 1st. Credit Suisse Group is getting its price on an icon from $ 131.00 to $ 144.00 and gives the company an "outperform" rating in a research note on Tuesday, June 19th. Finally, KeyCorp gets their price over $ 130.00 to $ 152.00 and gives the company an "overweight" rating in a research note on Monday, June 18th. Two investment badysts have rated the stock with a hold rating, and have had a strong buy rating. Icon has a consensus rating of "Buy" and a consensus target price of $ 133.70. </p>
<p> A number of institutional investors bought and sold shares of ICLR. Financial Gravity Wealth Inc. was acquired in the first quarter at $ 179,000. Gotham Asset Management LLC was acquired in the fourth quarter at $ 209,000. We Are One Seven LLC was acquired in the fourth quarter at $ 252,000. First National Bank of Omaha was sold at $ 279,000. Finally, Quantitative Systematic Strategies LLC was acquired in the first quarter at $ 296,000. Hedge funds and other institutional investors own 87.15% of the company's stock. </p>
<p> NASDAQ: ICLR traded up $ 1.80 during trading hours on Thursday, hitting $ 138.35. The company 's stock had a trading volume of 163,500 shares, compared to its average volume of 267,017. The firm has a market capitalization of $ 7.42 billion, a PE ratio of 25.67, a price-to-earnings-growth ratio of 2.15 and a beta of 0.45. The company has a quick ratio of 1.85, a current ratio of 1.85 and a debt-to-equity ratio of 0.29. Icon has a month of low $ 97.12 and a high month of $ 140.26. </p>
<p> <strong> Icon Company Profile </strong> </p>
<p> ICON Public Limited Company, Clinical Research Organization, Provides Outsourced Development Services to the Pharmaceutical, Biotechnology, and Medical Device Industries in Ireland, Rest of Europe, United States, and internationally. In the strategic development, management, and badysis of the clinical trials of various stages of the clinical development process from compound selection to Phase I-IV </p>
<p> Further Reading: Understanding the Relative Strength Index <br /> <!--ViewCount:type=c&tertiary=1&id=428840--> <!--Keyword: Icon,NASDAQ:ICLR,ICLR,Medical,Ratings,Consensus--> <!--Ratings:4,9,NASDAQ:ICLR--> </p>
<p> Zacks research report on the United States (1965) </p>
<p> For more information about Zacks Research Research, visit Zacks.com NASDAQ: ICLR) Receive News & Comments for Daily Icon </strong> – concise daily summary of the latest news and badysts' ratings for Icon and related companies MarketBeat.com's FREE daily email newsletter. </p>
<p><!-- End Footer Opt-In --></p></div>
</pre>
[ad_2]
<br /><a href=](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat.com/logos/icon-plc-logo.jpg){kind=icon}
Source link 